Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

Lancet

Volumn 363, Issue 9416, 2004, Pages 1179-1183

  Van Camp, Guy ^a   Flamez, Anja ^a   Cosyns, Bernard ^a   Weytjens, Caroline ^a   Muyldermans, Luc ^b   Van Zandijcke, Michel ^b   De Sutter, Johan ^c   Santens, Patrick ^c   Decoodt, Pierre ^d   Moerman, Christian ^d   Schoors, Danny ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b General Hospital St Jan   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MITRAL VALVE; PARKINSON DISEASE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

EID: 11144354035     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15945-X     Document Type: Article

References (18)

1. Shaunak S., Wilkins A., Pilling J.B., Dick D.J. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry. 66:1999;79-81.
2. Jimenez-Jimenez F.J., Lopez-Alvarez J., Sanchez-Chapado M., et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol. 18:1995;277-279.
3. Mondal B.K., Suri S. Pergolide-induced retroperitoneal fibrosis. Int J Clin Pract. 54:2000;403.
4. Danoff S.K., Grasso M.E., Terry P.B., Flynn J.A. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest. 120:2001;313-316.
5. Pritchett A.M., Morrison J.F., Edwards W.D., Schaff H.V., Connolly H.M., Espinosa R.E. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 77:2002;1280-1286.
6. Flowers C.M., Racoosin J.A., Lu S.L., Beitz J.G. The US food and drug administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc. 78:2003;730-731.
7. Rahimtoola S. Drug-related valvular heart disease: here we go again: will we do better this time. Mayo Clin Proc. 77:2002;1275-1277.
8. Van Camp G., Flamez A., Cosyns B., Goldstein J., Perdaens C., Schoors D. Valvular heart disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology. 61:2003;859-861.
9. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharm. 57:2000;75-81.
10. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 102:2000;2836-2841.
11. Setola V., Hufeisen S.J., Grande-Allen K.J., et al. 3,4- methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharm. 63:2003;1223-1229.
12. FDA. 2003 Safety Alert - Permax (pergolide mesylate). http://www.fda.gov/medwatch/SAFETY/2003/permax.htm (accessed Feb 27, 2004).
13. Lancellotti P., Lebrun F., Pierard L.A. Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 42:2003;1921-1928.
14. US Food and Drug Administration Center for Drug Evaluation and Research, and Center for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine. MMWR Morb Mortal Wkly Rep. 46:1997;1061-1066.
15. Shively B.K., Roldan C.A., Gill E.A., Najarian T., Loar S.B. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation. 100:1999;2161-2169.
16. Abenhaim L, Moride F, Brenot et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.
17. Delcroix M., Kurz X., Walckiers D., et al. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Eur Respir J. 12:1998;271-276.
18. Blanpain C., Le Poul E., Parma J., et al. Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res. 60:2003;518-528.